Related Experiment Video
Updated: Jun 1, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction.
Kei Yunoki1, Kazufumi Nakamura, Toru Miyoshi
1Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, 2-5-1, Shikata-Cho, Kita-ku, Okayama 700-8558, Japan. kei.yunoki@gmail.com
Atherosclerosis
|May 20, 2011
Summary
Postprandial hyperlipemia, characterized by high triglyceride levels after meals, impairs endothelial function. Ezetimibe treatment effectively reduces postprandial lipid levels and improves this diet-induced endothelial dysfunction.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Pharmacology
Background:
- Postprandial hyperlipemia is linked to endothelial dysfunction and atherosclerosis development.
- Understanding the relationship between postprandial lipid profiles and endothelial function is crucial for cardiovascular health.
Purpose of the Study:
- To investigate the association between postprandial lipid profiles and endothelial function.
- To examine the effects of ezetimibe on postprandial hyperlipemia and lipemia-induced endothelial dysfunction.
Main Methods:
- A randomized prospective trial involving 20 subjects (10 ezetimibe, 10 control) over 4 weeks.
- Lipid profiles and brachial artery flow-mediated dilation (FMD) were measured fasting and post-meal (2, 4, 6, 8 hours) before and after treatment.
Main Results:
- Pre-treatment, reduced postprandial %FMD correlated with increased triglyceride and apolipoprotein B-48 levels.
- Ezetimibe significantly reduced postprandial elevations in triglycerides, remnant lipoprotein cholesterol, and apoB-48.
- Ezetimibe treatment improved postprandial endothelial dysfunction (%FMD), while the control group showed no significant changes.
Conclusions:
- Postprandial hyperlipemia is closely associated with transient endothelial dysfunction.
- Ezetimibe demonstrates efficacy in improving both postprandial hyperlipemia and the resulting endothelial dysfunction.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:29Cholesterol: Significance and Regulation
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...